bluuebunny/crossref_metadata_2025_split huggingface dataset:
Extended elastic impedance for fluid and lithology prediction
Authors: Whitcombe David N. , Connolly Patrick A. , Reagan Roger L. , Redshaw Terry C. 
Published: October 2002

Constant angle projections of seismic sections can be designed to provide maximum discrimination between fluids or lithologies. The optimum projection for a noise‐free, isotropic environment can be obtained using an extension to the elastic impedance concept, which itself is an extension of acoustic impedance (AI) to nonzero angles of incidence. To achieve this, we modify the definition of elastic impedance (EI) beyond the range of physically meaningful angles by substituting tanχ for sin2 θ in the two‐term reflectivity equation. The primary variable now becomes χ rather than θ. We allow it to vary between −90° and +90°, which gives an extension of EI for any combination of intercept and gradient. We refer to this form of elastic impedance as extended elastic impedance (EEI). In this paper we demonstrate that EEI can be tuned using different χ values to be approximately proportional to a number of elastic parameters, and we give EEI expressions for shear impedance (SI), bulk modulus, shear modulus, Lamé's parameter, and Vp/Vs. This leads to the identification of different areas of EEI space that tend to be optimum for fluid and lithology imaging. Having identified an appropriate χ value, the equivalent seismic section can be obtained from combinations of intercept and gradient stacks from routine AVO processing.
Kirchhoff image propagation
Authors: Adler Frank 
Published: October 2002

Seismic imaging processes are, in general, formulated under the assumption of a correct macrovelocity model. However, seismic subsurface images are very sensitive to the accuracy of the macrovelocity model. This paper investigates how the output of Kirchhoff inversion/migration changes for perturbations of a given 3‐D laterally inhomogeneous macrovelocity model. The displacement of a reflector image point from a perturbation of the given velocity model is determined in a first‐order approximation by the corresponding traveltime and slowness perturbations as well as the matrix. of the Beylkin determinant. The required traveltime derivatives can be calculated with ray perturbation theory.Using this result, a new, computationally efficient Kirchhoff inversion/migration technique is developed to predict in parallel a series of subsurface images for perturbations of a given macrovelocity model during a single inversion/migration process applied to the unmigrated seismic data. These images are constructed by superposition of the seismic data at predicted image point locations which lie on surfaces that expand from the initial image point as a function of the velocity perturbation. Because of the analogy to Huygens wavefronts in wave propagation, the technique is called Kirchhoff image propagation.A 2‐D implementation of Kirchhoff image propagation requires about 1.2 times the computation time of a single migration to calculate a set of propagated images. The propagated images provide good approximations to remigrated images and are applied to migration velocity analysis.
Successful production application of 3‐D amplitude variation with offset: The lessons learned
Authors: Soroka William L. , Fitch Thomas J. , Van Sickle Kirk H. , North Philip D. 
Published: October 2002

Amplitude variation with offset (AVO) analysis was successfully performed on a 3‐D prestack seismic volume. Important conclusions were that AVO results could improve field development and production, that 3‐D AVO results were more useful than 2‐D AVO results, and that reliable AVO results could be generated on land. The AVO results were used to help develop an infill drilling program to increase production. AVO information lowered the risk of finding hydrocarbons by helping to identify seismic events that had a higher probability of being gas‐saturated sands. The 3‐D seismic survey covered known gas zones and potential new reserves. The AVO calibration work showed that positive AVO gas responses (classes 2 and 3) were observed for 90% of the zones associated with known production. One 15‐ft‐thick gas reservoir below seismic resolution did not give a positive AVO anomaly. A well drilled to an untested zone displaying a positive AVO anomaly encountered commercial quantities of gas. Production from this new zone at the initial flow rate increased the total production rate in this 25‐year‐old field by >50%. The AVO method was shown to be applicable onshore and to provide useful results in more consolidated geologic environments with classes 2 and 3 AVO responses. For the successful use of AVO, greater effort and extra care in acquisition and processing were needed than in a normal seismic program.
Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature
Authors: Wilson-Royalty Michele , Lawless Grant , Palmer Cynthia , Brown Ruth 
Published: October 2002

Purpose. This paper summarizes a literature review of the risk factors and predictors for chemo-therapy-related severe or febrile neutropenia (grades 3 and 4). It explores the extent to which the literature supports the current ASCO guidelines, and assesses the feasibility of developing a predictive algorithm for patients who would benefit from rHuG-CSF (Neupogen). Methods. An electronic literature search for English articles and abstracts identified 718 abstracts for review. From these, 121 articles were reviewed in depth. The review captured risk factors and predictors for grade 3-4 and/or febrile neutropenia, study design, patient characteristics, chemotherapy treatment, and the incidence of grade 3-4 and/or febrile neutropenia. Results. Twenty-eight potential risk factors and predictors for severe or febrile neutropenia among cancer patients were identified and could be classified as patient-related, treatment-related, or disease-related characteristics. Some results were inconsistent across studies due to a lack of standardized methods of assessment and reporting. Approximately 1/3 of the factors were mentioned in more than one study and provided information on the statistical significance of findings. Several factors had cross-study support of their value and confirmed previous findings. Strong predictors of severe/febrile neutropenia included advanced age, performance status, myelosuppressive chemotherapy regimen, early low blood counts, the depth of the absolute neutrophil count (ANC) nadir, and a precipitous, early drop in blood counts of all hematopoietic cell types. Conclusions. This literature review identified several key predictors and risk factors for development of grades 3 and 4 neutropenia in cancer patients. While additional confirmation is needed, there is sufficient consistency in the literature to support use of risk factors to identify patients who may need supportive care. Some of these risk factors were included in the ASCO CSF guidelines for the use of prophylactic support such as G-CSF; however, the ASCO publications have not included other important risk factors, such as age and early reduced ANC levels.
Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent
Authors: Osman Iman , Sherman Eric , Singh Bhuvanesh , Venkatraman Ennapadam , Zelefsky Michael , Bosl George , Scher Howard , Shah Jatin , Shaha Ashok , Kraus Dennis , Cordon-Cardo Carlos , Pfister David G. 
Published: October 2002

PURPOSE: To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent. PATIENTS AND METHODS: Seventy-one patients treated on two consecutive LP protocols were studied based on availability of representative tissues. We analyzed the expression pattern of p53, its upstream regulator mdm2, and downstream transcriptional target p21/WAF1 by immunohistochemistry. Positive phenotype was defined as ≥ 20% of tumor cells showing nuclear immunoreactivity. Results were correlated with treatment outcomes. RESULTS: Positive phenotype was observed in 35 (49%) of 71 cases for p53, in 52 (74%) of 70 for mdm2, and in 37 (54%) of 68 for p21. There was no correlation between p53 phenotype and p21 nuclear accumulation. The mdm2-negative phenotype was most predictive of major response at the primary tumor site (P = .088). p53-positive phenotype was associated with worse local control with LP (LCLP; 49% v 23%, P = .053) and inferior overall survival (OS; 51% v 29%, P = .017) at 5 years. On Cox regression analysis, p53-positive phenotype predicted inferior OS (P = .033) and showed a trend for worse LCLP (P = .102). When analyzed in a multivariate model as continuous variables, p53 showed a stronger correlation with inferior OS (P < .01), and mdm2 was associated with worse OS (P < .01). CONCLUSION: Among the three markers studied, our data support p53 phenotype as the most informative predictor of unfavorable outcomes in the LP setting, and suggest a role for mdm2 phenotype that requires further exploration. Our analysis does not support a p53-dependent mechanism for p21 expression. Prospective and larger studies are necessary before integration of these molecular markers as part of molecular staging and predictors for organ preservation or other outcomes.
Age at Diagnosis and Outcome for Women With Ductal Carcinoma-In-Situ of the Breast: A Critical Review of the Literature
Authors: Vicini Frank A. , Recht Abram 
Published: October 2002

PURPOSE: Patients younger than 35 to 45 years old at the time of diagnosis of invasive breast cancer have been found to have a worse prognosis than older patients in many studies. However, the impact of patient age at diagnosis on the outcome of treatment with either lumpectomy and radiation therapy (RT) or mastectomy for patients with ductal carcinoma-in-situ (DCIS) of the breast has not been extensively analyzed. MATERIALS AND METHODS: Articles addressing the effect of patient age at diagnosis on the outcome of treatment of DCIS with lumpectomy and RT or mastectomy were identified through the MEDLINE and CancerLit databases and reference lists of relevant articles. Studies were reviewed to determine the impact of patient age at diagnosis on clinical and pathologic features of DCIS, the influence of age on outcome after lumpectomy and RT, and the impact of age on outcome after mastectomy. RESULTS: DCIS in younger patients more frequently contains adverse prognostic pathologic factors and extends over a greater distance in the breast than in older patients. In series with adequate follow-up, younger patients treated with lumpectomy and RT had a significantly higher rate of local recurrence than older patients, especially for invasive local recurrences. Some studies have suggested that careful attention to margin status and excising larger volumes of tissue can reduce this difference substantially. No available data show that younger patients have better long-term cancer-free survival rates if treated by mastectomy rather than lumpectomy and RT. CONCLUSION: Successful treatment of younger patients with DCIS with lumpectomy and RT requires careful attention to patient evaluation, selection, and surgical technique. When this is done, age at diagnosis should not be a contraindication to breast-conserving therapy.
Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement
Authors: Sarris A. H. , Phan A. , Duvic M. , Romaguera J. , McLaughlin P. , Mesina O. , King K. , Medeiros L. J. , Rassidakis G. Z. , Samuels B. , Cabanillas F. 
Published: October 2002

PURPOSE: Methotrexate (MTX) is active against lymphomas, but transport or polyglutamylation mutations confer MTX resistance. Because trimetrexate (TMTX) enters cells by passive diffusion and is not polyglutamylated, its activity in relapsed T-cell lymphoma was investigated. PATIENTS AND METHODS: Eligible patients had histologically confirmed relapsed T-cell lymphoma involving the skin, had received more than one previous regimen, were older than 16 years, had normal organ function, and had no CNS disease or serious infections, including human immunodeficiency virus. TMTX (200 mg/m2) was given intravenously every 14 days without topical or systemic corticosteroids. Patients who responded received up to 12 doses. RESULTS: Twenty patients were assessable for response. Median age was 59 years (range, 45 to 87 years); 13 patients were men. Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sézary syndrome (14 with large-cell transformation), and two had peripheral T-cell lymphoma. Serum lactate dehydrogenase was high in 35%, and beta-2 microglobulin was more than 3.0 mg/L in 35% of patients. The median number of previous regimens was three (range, two to 15) and included MTX in five patients. Disease was refractory to the regimen immediately preceding TMTX in 85% of patients. Responses were complete in one and partial in eight patients (overall response rate, 45%). Two of five patients previously treated with MTX responded. Grade 3 or 4 mucositis was observed after 4%, infection after 3%, neutropenic fever after 6%, neutrophils less than 100/μL after 4%, and platelets less than 10,000/μL after 3% of TMTX doses. CONCLUSION: TMTX is active with acceptable toxicity in this population and merits further investigation.
Incipient Angiogenesis in Barrett’s Epithelium and Lymphangiogenesis in Barrett’s Adenocarcinoma
Authors: Auvinen Merja I. , Sihvo Eero I.T. , Ruohtula Terhi , Salminen Jukka T. , Koivistoinen Aki , Siivola Päivi , Rönnholm Ragna , Rämö Juhani O. , Bergman Mathias , Salo Jarmo A. 
Published: October 2002

PURPOSE: Barrett’s esophagus (BE), a precancerous condition for Barrett’s adenocarcinoma, is classically characterized by flames of salmon-colored mucosa extending into normal pale esophageal mucosa. This flaming is thought to be a consequence of continuous erosis of mucosa caused by chronic reflux. Another characteristic feature of Barrett’s adenocarcinoma patients is the frequent development of lymph node metastases. We addressed whether onset of angiogenesis occurs in BE and if the lymphatic system might provide a route for Barrett’s adenocarcinoma cells to infiltrate regular lymph nodes.PATIENTS AND METHODS: Fifteen surgically resected Barrett’s dysplasia or adenocarcinoma patients were included. Immunohistochemistry and a modified whole mount analysis were used.RESULTS: The incipient angiogenesis originates from the pre-existing vascular network in the lamina propria and infiltrates Barrett’s epithelium, giving its ominous salmon-red color. Barrett’s epithelium–specific goblet cells express vascular endothelial growth factor (VEGF)-A. The immature blood vessels show a relative absence of smooth muscle actin (SMA)-positive mural cells and express VEGF receptor (VEGFR)-2 and matrix metalloproteinase (MMP)-9 on their exterior. Coexpression of VEGF-C and its receptor VEGFR-3 on lymphatic vessels is demonstrated.CONCLUSION: BE is strongly neovascularized not eroded. This novel concept of a molecular mechanism of the origin of BE might emphasize why precancerous BE can give rise to the more cancerous dysplasia and Barrett’s adenocarcinoma stages. In addition, adenocarcinoma cells induce lymphangiogenesis. The new lymphangiogenic vessels might provide a systemic route for adenocarcinoma cells to invade circulation and induce lymph node metastasis.
Chronic Arm Morbidity After Curative Breast Cancer Treatment: Prevalence and Impact on Quality of Life
Authors: Kwan Winkle , Jackson Jeremy , Weir Lorna M. , Dingee Carol , McGregor Greg , Olivotto Ivo A. 
Published: October 2002

PURPOSE: To determine the prevalence of and contributing factors for chronic arm morbidity including lymphedema in breast cancer patients after treatment and to assess the impact of arm morbidity on quality of life (QOL). PATIENTS AND METHODS: A four-question screening questionnaire was developed and mailed to a random sample of 744 breast cancer patients treated curatively in two cancer centers from 1993 to 1997. Patients were without recurrence and at least 2 years from diagnosis. Respondents were classified as with or without arm-related symptoms on the basis of the survey. Stratified random samples from each group were then invited for a detailed assessment of their symptoms and signs, including the presence of lymphedema. Their QOL was assessed by the European Organization for Research and Treatment of Cancer QOL Questionnaire C-30 and by a detailed arm problem questionnaire that assessed various aspects of daily arm functioning. RESULTS: Approximately half of all screened patients were symptomatic and 12.5% of all assessed patients had lymphedema. Axillary dissection (AD) and axillary radiotherapy (RT) after dissection were statistically significantly related to the occurrence of arm symptoms (odds ratio for AD = 3.3, P < .001; odds ratio for RT = 3.1, P < .001). Symptomatic patients and patients with lymphedema both had impaired QOL compared with asymptomatic patients. CONCLUSION: Treatment for breast cancer is associated with considerable arm morbidity, which has a negative impact on QOL. Arm morbidity should be carefully monitored in future studies involving local treatment modalities for breast cancer.
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
Authors: Belli Filiberto , Testori Alessandro , Rivoltini Licia , Maio Michele , Andreola Giovanna , Sertoli Mario Roberto , Gallino Gianfrancesco , Piris Adriano , Cattelan Alessandro , Lazzari Ivano , Carrabba Matteo , Scita Giorgio , Santantonio Cristina , Pilla Lorenzo , Tragni Gabrina , Lombardo Claudia , Arienti Flavio , Marchianò Alfonso , Queirolo Paola , Bertolini Francesco , Cova Agata , Lamaj Elda , Ascani Lucio , Camerini Roberto , Corsi Marco , Cascinelli Natale , Lewis Jonathan J. , Srivastava Pramod , Parmiani Giorgio 
Published: October 2002

PURPOSE: To determine the immunogenicity and antitumor activity of a vaccine consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients.PATIENTS AND METHODS: Sixty-four patients had surgical resection of metastatic tissue required for vaccine production, 42 patients were able to receive the vaccine, and 39 were assessable after one cycle of vaccination (four weekly injections). In 21 patients, a second cycle (four biweekly injections) was given because no progression occurred. Antigen-specific antimelanoma T-cell response was assessed by enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMCs) obtained before and after vaccination. Immunohistochemical analyses of tumor tissues were also performed.RESULTS: No treatment-related toxicity was observed. Of 28 patients with measurable disease, two had a complete response (CR) and three had stable disease (SD) at the end of follow-up. Duration of CR was 559+ and 703+ days, whereas SD lasted for 153, 191, and 272 days, respectively. ELISPOT assay with PBMCs of 23 subjects showed a significantly increased number of postvaccination melanoma-specific T-cell spots in 11 patients, with clinical responders displaying a high frequency of increased T-cell activity. Immunohistochemical staining of melanoma tissues from which vaccine was produced revealed high expression of both HLA class I and melanoma antigens in seven of eight clinical responders (two with CR, three with SD, and the three with long-term disease-free survival) and in four of 12 nonresponders.CONCLUSION: Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity. This vaccine induced clinical and tumor-specific T-cell responses in a significant minority of patients.
Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma
Authors: Pagliaro Lance C. , Millikan Randall E. , Tu Shi-Ming , Williams Dallas , Daliani Danai , Papandreou Christos N. , Logothetis Christopher J. 
Published: October 2002

PURPOSE: We investigated the feasibility, safety, and antitumor activity of weekly gemcitabine given in combination with low doses of cisplatin and ifosfamide in previously treated patients with advanced transitional-cell carcinoma (TCC) of the urothelium. PATIENTS AND METHODS: Patients with measurable, metastatic or unresectable TCC who had received one or two prior chemotherapy regimens were eligible. On a 28-day course, doses of cisplatin 30 mg/m2, gemcitabine 800 mg/m2, and ifosfamide 1 g/m2 were given on day 1 and then repeated on day 8 and day 15 unless there was dose-limiting hematologic toxicity. RESULTS: Fifty-one patients were registered; 10 patients participated in a pilot study, after which 41 patients were registered onto the phase II protocol. Forty-eight patients (94.1%) had dose-limiting hematologic toxicity on day 8 or day 15. Nonhematologic toxicity of grade 3 or greater consisted mainly of nausea and vomiting (seven patients, 13.7%) and infection (seven patients, 13.7%). Responses could be assessed in 49 of 51 eligible patients; two complete responses (4.1%) and 18 partial responses (36.7%) were observed for an overall response rate of 40.8% (exact 95% confidence interval, 27% to 56%). CONCLUSION: This regimen of cisplatin, gemcitabine, and ifosfamide is not feasible for weekly administration because of hematologic toxicity. Nevertheless, there was promising activity with only two doses per 28-day cycle. On the basis of these results, we have initiated a phase II trial of this combination given as a single dose every 14 days in patients with untreated, metastatic urothelial carcinoma.
Supernumerary digital flexion creases: An additional clinical manifestation of Alagille syndrome
Authors: Kamath Binita M. , Loomes Kathleen M. , Oakey Rebecca J. , Krantz Ian D. 
Published: October 2002

AbstractAlagille syndrome (AGS; OMIM 118450) is a complex dominantly inherited multisystem disorder involving the liver, heart, eyes, facies, skeleton, and other systems. Criteria for the clinical diagnosis have been established as the presence of bile duct paucity on liver biopsy in association with three of five major clinical findings (cholestasis, butterfly vertebrae, posterior embryotoxon, congenital heart disease, and facial features). Jagged1 has been identified as the AGS disease gene. Jagged1 is a large gene, with no mutational hot spots, making molecular testing difficult at this time. Other clinical features would prove helpful in establishing the diagnosis in the absence of molecular confirmation. Supernumerary digital flexion creases have been identified in 16/46 (35%) of AGS probands examined through the Alagille Syndrome Diagnostic Center at the Children's Hospital of Philadelphia. Although digital abnormalities have been noted in AGS in the past, including short distal phalanges and fifth finger clinodactyly, digital crease abnormalities have never before been reported. Supernumerary digital creases have been reported in less than 1% of the general population. The presence of extra and missing digital creases in individuals with normal joint anatomy, their occurrence in several syndromes, and mouse in situ expression studies indicate that genetic factors contribute to digital crease formation. However, these factors are poorly understood. Hypotheses regarding the origin of flexion creases are discussed. The identification of supernumerary digital creases in one‐third of AGS probands provides another diagnostic aid and allows for speculation of the role of Jagged1 in the molecular development of digital crease patterns. © 2002 Wiley‐Liss, Inc.